📇 Rhumatologue · ST NAZAIRE CEDEX · (44) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
129.9 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CH DE SAINT NAZAIRE
CITE SANITAIRE GEORGES CHARPAK 11 BD GEORGES CHARPAK BP 414, 44606 ST NAZAIRE CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Osteoarthritis and cartilage open · 2021
ERJ open research · 2024
IntroductionNon-small cell lung cancer (NSCLC) is often associated with compromised lung function. Real-world data on the impact of surgical approach in NSCLC patients with compromised lung function are still lacking. The objective of this study is to assess the potential impact of minimally invasive surgery (MIS) on 90-day post-operative mortality after anatomic lung resection in high-risk operable NSCLC patients.MethodsWe conducted a retrospective multicentre study including all patients who underwent anatomic lung resection between January 2010 and October 2021 and registered in the Epithor database. High-risk patients were defined as those with a forced expiratory volume in 1 s (FEV1) or diffusing capacity of the lung for carbon monoxide (DLCO) value below 50%. Co-primary end-points were the impact of risk status on 90-day mortality and the impact of MIS on 90-day mortality in high-risk patients.ResultsOf the 46 909 patients who met the inclusion criteria, 42 214 patients (90%) with both preoperative FEV1andDLCOabove 50% were included in the low-risk group, and 4695 patients (10%) with preoperative FEV1and/or preoperativeDLCObelow 50% were included in the high-risk group. The 90-day mortality rate was significantly higher in the high-risk group compared to the low-risk group (280 (5.96%)versus1301 (3.18%); p<0.0001). In high-risk patients, MIS was associated with lower 90-day mortality compared to open surgery in univariate analysis (OR=0.04 (0.02–0.05), p<0.001) and in multivariable analysis after propensity score matching (OR=0.46 (0.30–0.69), p<0.001). High-risk patients operated through MIS had a similar 90-day mortality rate compared to low-risk patients in general (3.10%versus3.18% respectively).ConclusionBy examining the impact of surgical approaches on 90-day mortality using a nationwide database, we found that either preoperative FEV1orDLCObelow 50% is associated with higher 90-day mortality, which can be reduced by using minimally invasive surgical approaches. High-risk patients operated through MIS have a similar 90-day mortality rate as low-risk patients.
Critical care (London, England) · 2025
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Annales pharmaceutiques francaises · 2026 · English Abstract
Eva G, Arthur DB, Anne K, Fabrice G, et al.
JMIR medical informatics · 2025 · Journal Article
Cissé M, Niang M, Anne A, Sidibé M, et al.
ERJ open research · 2024 · Journal Article
Etienne H, Pagès PB, Iquille J, Falcoz PE, et al.
Osteoarthritis and cartilage open · 2021 · Journal Article
A D, A T, T J, O R, et al.
Acta chirurgica Belgica · 1985 · Journal Article
Hamerlijnck R, Flamme A, Nijboer JH, Anné T, et al.
EJC paediatric oncology · 2025 · Journal Article
Mallon B, Dial C, Akonde FB, Ahouidi MJD, et al.
Critical care (London, England) · 2025 · Journal Article
Maamar A, Faleur C, Pedrono K, Adeux MP, et al.
EJC paediatric oncology · 2025 · Journal Article
Mallon B, Dial C, Akonde FB, Ahouidi MJD, et al.